Matsubayashi and colleagues reported that tofogliflozin, another iSGLT2, significantly increases hepatic insulin clearance, reduces triglyceride levels, and elevates BHB levels, as well as contributes to hyperinsulinemia correction in T2D patients [166]. The gene discussed is INS; the disease is type 2 diabetes mellitus.